Piramal Pharma Ltd Financials
Company Logo

Piramal Pharma Ltd Financial Statement

Piramal Pharma Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue1390.77
Operating Expense1031.50
Net Profit210.06
Net Profit Margin15.10
Earning Per Share1.59
EBIDTA355.25
Effective Tax Rate17.15
Invest in Piramal Pharma Ltd
₹0 Brokerage*
Open Demat Account
*By signing up you agree to our Terms and Conditions

Piramal Pharma Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual4,390.11
Operating Expenses Annual3,772.19
Operating Profit Annual819.98
Interest Annual107.10
Depreciation205.26
Net Profit Annual391.22
Tax Annual116.40

Piramal Pharma Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning54.28
Cash Flow from Operations358.29
Cash Flow from Investing-635.15
Cash Flow from Financing451.38
Cash Flow at the End228.80

Piramal Pharma Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)18.68
PBIT Margin (%)14
PBT Margin (%)13.87
Net PROFIT Margin (%)8.91
Return On Networth / Equity (%)6.53
Return On Networth /Employed (%)8.27
Return On Assets (%)5.26
Total Debt / Equity (X)0.24
Asset Turnover Ratio (%)0.59

Piramal Pharma Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual2,913
Total Current Assets Annual3,291.55
Non Current Assets Annual6,259.33
Total Shareholders Funds Annual6,712.07
Total Assets Annual9,550.88

Piramal Pharma Ltd Earning Calls

EPS (INR)

Expected

0.17

Reported

0.17

Surprise

0.00%

Jun 2024

EPS beaten by 0.00%

Mar 2024

EPS beaten by 0.00%

Dec 2023

EPS beaten by 0.00%

Get Your FAQs Right

As of Nov 23, 2024, Piramal Pharma Ltd has a market capitalization of 17,052.80 Cr. Value Research classifies it as a Large-Cap company.
Yes, Piramal Pharma Ltd is debt-free with a debt-to-equity ratio of 0.18.
In FY 2023 , Piramal Pharma Ltd recorded a total revenue of approximately 4,390.11 Cr marking a significant milestone in the company's financial performance.
Piramal Pharma Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately Infinity% and 0.1% annually, respectively..
Piramal Pharma Ltd's current PE ratio is 43.59.
Piramal Pharma Ltd's ROCE averaged 6.5% from the FY ending March 2022 to 2024, with a median of 7.8%. It peaked at 8.3% in March 2022, reflecting strong capital efficiency over the period..
Piramal Pharma Ltd's latest EBIT is Rs. 614.72 Cr, surpassing the average EBIT of Rs. 457.97 Cr over the 5 years..